|1.||Wisniecki, Ania: 1 article (01/2005)|
|2.||Salamone, John D: 1 article (01/2005)|
|3.||Rios, Clifford: 1 article (01/2005)|
|4.||Lentini, Elizabeth: 1 article (01/2005)|
|5.||Betz, Adrienne: 1 article (01/2005)|
|6.||Correa, Merce: 1 article (01/2005)|
|7.||Carlson, Brian B: 1 article (01/2005)|
|1.||Parkinson Disease (Parkinson's Disease)
06/01/1989 - "A double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208-243 in patients with Parkinson's disease."
10/16/1992 - "The D1-selective agonist, CY 208-243, generated a dose-dependent locomotor response in this animal model for Parkinson's disease; low doses elicited little or no effect while higher doses resulted in a short burst of locomotor activity (2 h). "
01/01/1992 - "Effects of a selective partial D1 agonist, CY 208-243, in de novo patients with Parkinson disease."
01/01/1992 - "A selective dopamine D1-receptor agonist, CY 208-243, was administered to 23 de novo patients who had had Parkinson disease (PD) for less than or equal to 3 months. "
01/01/1989 - "Single morning doses of CY 208-243 (5-40 mg) were compared with the usual morning dose of levodopa in eight patients with Parkinson's disease on long-term levodopa therapy who had developed motor fluctuations from immobility with akinesia and rigidity (off) to mobility often with dyskinesias (on). "
01/01/1992 - "Results showed that CY 208-243 exerted a mild antiparkinsonian action, and tremor was the main symptom that consistently improved. "
01/30/2005 - "The selective D2 agonist ropinirole, which also is used clinically as an antiparkinsonian drug, suppressed jaw movements in the dose range of 2.5-20.0 mg/kg. The D1 agonist CY 208-243, which has been reported to suppress tremor, also reduced jaw movement activity (4.0 mg/kg). "
01/01/1992 - "The antitremor effect of the D2 agonist LY 171555 and of the D1 agonist CY 208-243 alone and in combination was tested in a monkey previously rendered parkinsonian by MPTP and displaying exceptionally a rest tremor in the limbs. "
01/01/1992 - "Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism."
07/01/1995 - "2. Addition of CY 208-243 increased the therapeutic response observed with the ergot alone without inducing dyskinesia. "
11/26/1993 - "All animals showed a dose-dependent improvement of their parkinsonian signs after the chronic CY 208-243 treatment; however, half of them developed peak-dose dyskinesias. "
08/01/1992 - "The substitution by CY 208-243 reproduced the same dyskinesia observed with (+)-PHNO. "
01/01/1989 - "CY 208-243 alone was capable of switching such patients from off to on; five of the eight patients responded to the highest dose (40 mg), sometimes with dyskinesias. "
11/26/1993 - "The extent of striatal DA denervation, decreased D1, elevated D2 and GABAA receptors, as well as the decrease of the D1/D2 receptor ratio in the posterior striatum may be involved in the appearance of dyskinesias after chronic CY 208-243 treatment."
|4.||Parkinsonian Disorders (Parkinsonism)
12/04/1990 - "Intrastriatal SKF 38393 or CY 208-243 neither facilitated nor ameliorated pilocarpine-induced convulsions. "
08/01/1990 - "When administered in conjunction with a minimally effective quantity of CY 208-243 (0.375 mg/kg), however, all five neuroleptics interacted synergistically with the D-1 agonist to promote convulsions to pilocarpine (100 mg/kg). "
08/01/1990 - "Pretreatment with the D-1 agonist CY 208-243 (0.375-1.5 mg/kg) dose-dependently potentiated the convulsions elicited by 100 mg/kg pilocarpine, but had neither a convulsant nor anticonvulsant effect in mice receiving picrotoxin (3 or 6 mg/kg) or strychnine (0.75 or 1.5 mg/kg). "
|1.||Dopamine Agonists (Dopamine Agonist)
|2.||2,3,4,5- Tetrahydro- 7,8- dihydroxy- 1- phenyl- 1H- 3- benzazepine (SKF 38393)
|3.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
|5.||Levodopa (L Dopa)
|7.||4,4a,5,6,7,8,8a,9- octahydro- 5- propyl- 1H- pyrzolo(3,4- g)quinoline
|8.||Dopamine D2 Receptors (Dopamine D2 Receptor)
|9.||Dopamine D1 Receptors (Dopamine D1 Receptor)
|10.||Antipsychotic Agents (Antipsychotics)